Frontiers in Medicine (Sep 2017)

Proteomics of Eosinophil Activation

  • Deane F. Mosher,
  • Deane F. Mosher,
  • Emily M. Wilkerson,
  • Keren B. Turton,
  • Alexander S. Hebert,
  • Joshua J. Coon,
  • Joshua J. Coon

DOI
https://doi.org/10.3389/fmed.2017.00159
Journal volume & issue
Vol. 4

Abstract

Read online

We recently identified and quantified >7,000 proteins in non-activated human peripheral blood eosinophils using liquid chromatography coupled to tandem mass spectrometry (LC–MS/MS) and described phosphoproteomic changes that accompany acute activation of eosinophils by interleukin-5 (IL5) (1). These data comprise a treasure trove of information about eosinophils. We illustrate the power of label-free LC–MS/MS quantification by considering four examples: complexity of eosinophil STATs, contribution of immunoproteasome subunits to eosinophil proteasomes, complement of integrin subunits, and contribution of platelet proteins originating from platelet–eosinophil complexes to the overall proteome. We describe how isobaric labeling enables robust sample-to-sample comparisons and relate the 220 phosphosites that changed significantly upon treatment with IL5 to previous studies of eosinophil activation. Finally, we review previous attempts to leverage the power of mass spectrometry to discern differences between eosinophils of healthy subjects and those with eosinophil-associated conditions and point out features of label-free quantification and isobaric labeling that are important in planning future mass spectrometric studies.

Keywords